Board and Committee changes
For media and investors only
Issued: London UK
GSK plc (LSE/NYSE: GSK) has today announced the following changes to its Board and Committees, which took effect immediately following the demerger of the Consumer Healthcare business on Monday 18 July 2022 (the Demerger):
- Charles Bancroft has succeeded Vindi Banga as Senior Independent Non-Executive Director. Mr Bancroft has also been appointed a member of the Remuneration Committee.
- Urs Rohner has been appointed a member of the Audit & Risk Committee.
- Dr Anne Beal has been appointed a member of the Remuneration and Nominations & Corporate Governance committees.
- Dr Vishal Sikka who joined the Board on 18 July 2022 has been appointed a member of the Corporate Responsibility Committee. In addition, Dr Sikka will attend Audit & Risk Committee meetings to support the Committee’s oversight of GSK’s Digital and Technology programme.
The Board has determined that given the refreshment of the Board following the Demerger and the Company’s renewed focus the whole Board will engage with the workforce to gather employees’ perspectives rather than designating a specific Non-Executive Director for this purpose. A programme of events is in place to facilitate engagement with employees to gather and understand directly their views.
As previously announced:
- Vindi Banga and Dame Vivienne Cox stepped down from the GSK Board upon their appointments to the Haleon plc Board effective on Demerger.
- Lynn Elsenhans retired from the Board effective from the Demerger.
These changes continue the transition of the Board as an independent biopharma company post separation. GSK expects to announce further Non-Executive Director appointments shortly.
Board and Committee Membership with effect from 18 July 2022:
| Board Membership | |
|---|---|
|
Sir Jonathan Symonds Emma Walmsley Iain Mackay Dr Hal Barron* Charles Bancroft Dr Anne Beal Dr Hal Dietz Dr Laurie Glimcher Dr Jesse Goodman Urs Rohner Dr Vishal Sikka |
Non-Executive Chair Chief Executive Officer Chief Financial Officer Chief Scientific Officer Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director |
*Dr Barron will transition to a Non-Independent Non-Executive Director with effect from 1 August 2022.
| Board Committee | Committee Chair | Members |
|---|---|---|
|
Audit & Risk Committee |
Charles Bancroft* |
Dr Anne Beal Dr Laurie Glimcher Urs Rohner |
|
Remuneration Committee |
Urs Rohner |
Charles Bancroft Dr Anne Beal |
|
Nominations & Corporate Governance Committee |
Sir Jonathan Symonds |
Charles Bancroft Dr Anne Beal Urs Rohner |
|
Corporate Responsibility Committee |
Dr Anne Beal |
Dr Jesse Goodman Dr Vishal Sikka |
|
Science Committee |
Dr Jesse Goodman** |
Dr Hal Dietz** Dr Laurie Glimcher** Dr Hal Barron (wef 1 August 2022) |
|
Chairs’ Committee |
Sir Jonathan Symonds |
Senior Independent Non-Executive Director Chairs of the Board’s Committees |
* Audit committee financial expert
** Scientific and Medical Expert
Victoria Whyte
Company Secretary
22 July 2022
Notes
|
A. The following information is available for reference on www.GSK.com: |
||
|
1 |
Biographies of each Board member |
|
|
2 |
Terms of reference of each Board Committee |
|
|
3 |
Current Non-Executive Director Fees |
Non-Executive Director Fees |
|
B. |
Mr Bancroft’s annual fee increased by £50,000 per annum when he became GSK’s Senior Independent Non-Executive Director. |
|
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q1 Results for 2022 and any impacts of the COVID-19 pandemic.
